BDX vs. BIIB: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BDX and BIIB, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BDX | BIIB |
|---|---|---|
| Company Name | Becton, Dickinson and Company | Biogen Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 55.03 billion USD | 22.59 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | February 21, 1973 | September 17, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BDX and BIIB by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BDX | BIIB |
|---|---|---|
| 5-Day Price Return | 2.58% | 9.97% |
| 13-Week Price Return | 11.01% | 18.38% |
| 26-Week Price Return | -15.06% | 16.68% |
| 52-Week Price Return | -19.11% | -16.63% |
| Month-to-Date Return | 2.58% | 9.97% |
| Year-to-Date Return | -15.37% | 0.74% |
| 10-Day Avg. Volume | 1.41M | 1.96M |
| 3-Month Avg. Volume | 2.43M | 1.54M |
| 3-Month Volatility | 27.47% | 37.69% |
| Beta | 0.26 | 0.12 |
Profitability
Return on Equity (TTM)
BDX
6.31%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
BDX’s Return on Equity of 6.31% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
BIIB
9.04%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BDX
7.51%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
BDX’s Net Profit Margin of 7.51% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
BIIB
15.31%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BDX
11.83%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
BDX’s Operating Profit Margin of 11.83% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
BIIB
20.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
BIIB’s Operating Profit Margin of 20.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BDX | BIIB |
|---|---|---|
| Return on Equity (TTM) | 6.31% | 9.04% |
| Return on Assets (TTM) | 2.90% | 5.43% |
| Net Profit Margin (TTM) | 7.51% | 15.31% |
| Operating Profit Margin (TTM) | 11.83% | 20.80% |
| Gross Profit Margin (TTM) | 45.08% | 75.43% |
Financial Strength
Current Ratio (MRQ)
BDX
1.10
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
BDX’s Current Ratio of 1.10 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
BIIB
2.50
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BIIB’s Current Ratio of 2.50 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BDX
0.76
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
BDX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
BIIB
0.36
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BDX
5.93
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
BDX’s Interest Coverage Ratio of 5.93 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | BDX | BIIB |
|---|---|---|
| Current Ratio (MRQ) | 1.10 | 2.50 |
| Quick Ratio (MRQ) | 0.46 | 1.79 |
| Debt-to-Equity Ratio (MRQ) | 0.76 | 0.36 |
| Interest Coverage Ratio (TTM) | 5.93 | 4.35 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BDX
2.13%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.13%, BDX offers a more attractive income stream than most of its peers in the Health Care Equipment & Supplies industry, signaling a strong commitment to shareholder returns.
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BDX
73.10%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
BDX’s Dividend Payout Ratio of 73.10% is in the upper quartile for the Health Care Equipment & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BDX | BIIB |
|---|---|---|
| Dividend Yield (TTM) | 2.13% | 0.00% |
| Dividend Payout Ratio (TTM) | 73.10% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BDX
34.38
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
BDX’s P/E Ratio of 34.38 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
BIIB
14.78
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 14.78 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BDX
2.58
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
BDX’s P/S Ratio of 2.58 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
BIIB
2.26
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.26 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BDX
1.94
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
BDX’s P/B Ratio of 1.94 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
BIIB
1.04
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BDX | BIIB |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 34.38 | 14.78 |
| Price-to-Sales Ratio (TTM) | 2.58 | 2.26 |
| Price-to-Book Ratio (MRQ) | 1.94 | 1.04 |
| Price-to-Free Cash Flow Ratio (TTM) | 21.65 | 12.25 |